FDA asks AstraZeneca for more data on Nexium applications

06/1/2010 | ABC News

The FDA told AstraZeneca it needs more information before it can approve applications to market Axanum, a combination of aspirin and esomeprazole, and the supplemental use of Nexium for reducing the risk of low-dose aspirin-associated peptic ulcers. AstraZeneca wants to extend the life of the well-received acid reflux drug Nexium, which is facing loss of patent protection in key markets.

View Full Article in:

ABC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA